Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review

Luciano Mariani, Patrizia Vici, Barbara Suligoi, Giovanni Checcucci-Lisi, Rosybel Drury

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Introduction: Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination.

Methods: We performed a systematic literature search in PubMed to identify all published studies on 4HPV vaccination, including those that assessed the impact of 4HPV vaccination programs on the incidence of GWs at a population level around the world.

Results: A total of 354 records were identified in the PubMed search. After screening and obtaining full papers for 56 publications, 16 publications presenting data on the impact or effectiveness of 4HPV vaccination on GWs were identified. These reported data on the impact or effectiveness of 4HPV in six countries [Australia (n = 6), New Zealand (n = 2), United States (n = 3), Denmark (n = 2), Germany (n = 1), and Sweden (n = 2)]. In Australia, no GWs were diagnosed in women aged

Conclusion: The results are coherent with the GWs incidence reduction reported in clinical trials and are an early indicator of what can be expected for the long-term clinical impact on vaccine-type HPV-related cancers.

Original languageEnglish
Pages (from-to)10-30
Number of pages21
JournalAdvances in Therapy
Volume32
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Papillomavirus Vaccines
Condylomata Acuminata
Vaccination
PubMed
Publications
Clinical Trials
Neoplasms
Cancer Vaccines
Incidence
Denmark
Infection
New Zealand
Sweden
Uterine Cervical Neoplasms
Germany
Vaccines
Population

Keywords

  • 4HPV vaccine
  • Gardasil
  • Genital warts
  • Human papillomavirus
  • Quadrivalent human papillomavirus vaccine
  • Vaccine effectiveness
  • Vaccine impact

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts : a Systematic Review. / Mariani, Luciano; Vici, Patrizia; Suligoi, Barbara; Checcucci-Lisi, Giovanni; Drury, Rosybel.

In: Advances in Therapy, Vol. 32, No. 1, 2015, p. 10-30.

Research output: Contribution to journalArticle

Mariani, Luciano ; Vici, Patrizia ; Suligoi, Barbara ; Checcucci-Lisi, Giovanni ; Drury, Rosybel. / Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts : a Systematic Review. In: Advances in Therapy. 2015 ; Vol. 32, No. 1. pp. 10-30.
@article{6ff35944fcec41508b2361af1fbe2c2c,
title = "Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review",
abstract = "Introduction: Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination.Methods: We performed a systematic literature search in PubMed to identify all published studies on 4HPV vaccination, including those that assessed the impact of 4HPV vaccination programs on the incidence of GWs at a population level around the world.Results: A total of 354 records were identified in the PubMed search. After screening and obtaining full papers for 56 publications, 16 publications presenting data on the impact or effectiveness of 4HPV vaccination on GWs were identified. These reported data on the impact or effectiveness of 4HPV in six countries [Australia (n = 6), New Zealand (n = 2), United States (n = 3), Denmark (n = 2), Germany (n = 1), and Sweden (n = 2)]. In Australia, no GWs were diagnosed in women aged Conclusion: The results are coherent with the GWs incidence reduction reported in clinical trials and are an early indicator of what can be expected for the long-term clinical impact on vaccine-type HPV-related cancers.",
keywords = "4HPV vaccine, Gardasil, Genital warts, Human papillomavirus, Quadrivalent human papillomavirus vaccine, Vaccine effectiveness, Vaccine impact",
author = "Luciano Mariani and Patrizia Vici and Barbara Suligoi and Giovanni Checcucci-Lisi and Rosybel Drury",
year = "2015",
doi = "10.1007/s12325-015-0178-4",
language = "English",
volume = "32",
pages = "10--30",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "1",

}

TY - JOUR

T1 - Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts

T2 - a Systematic Review

AU - Mariani, Luciano

AU - Vici, Patrizia

AU - Suligoi, Barbara

AU - Checcucci-Lisi, Giovanni

AU - Drury, Rosybel

PY - 2015

Y1 - 2015

N2 - Introduction: Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination.Methods: We performed a systematic literature search in PubMed to identify all published studies on 4HPV vaccination, including those that assessed the impact of 4HPV vaccination programs on the incidence of GWs at a population level around the world.Results: A total of 354 records were identified in the PubMed search. After screening and obtaining full papers for 56 publications, 16 publications presenting data on the impact or effectiveness of 4HPV vaccination on GWs were identified. These reported data on the impact or effectiveness of 4HPV in six countries [Australia (n = 6), New Zealand (n = 2), United States (n = 3), Denmark (n = 2), Germany (n = 1), and Sweden (n = 2)]. In Australia, no GWs were diagnosed in women aged Conclusion: The results are coherent with the GWs incidence reduction reported in clinical trials and are an early indicator of what can be expected for the long-term clinical impact on vaccine-type HPV-related cancers.

AB - Introduction: Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination.Methods: We performed a systematic literature search in PubMed to identify all published studies on 4HPV vaccination, including those that assessed the impact of 4HPV vaccination programs on the incidence of GWs at a population level around the world.Results: A total of 354 records were identified in the PubMed search. After screening and obtaining full papers for 56 publications, 16 publications presenting data on the impact or effectiveness of 4HPV vaccination on GWs were identified. These reported data on the impact or effectiveness of 4HPV in six countries [Australia (n = 6), New Zealand (n = 2), United States (n = 3), Denmark (n = 2), Germany (n = 1), and Sweden (n = 2)]. In Australia, no GWs were diagnosed in women aged Conclusion: The results are coherent with the GWs incidence reduction reported in clinical trials and are an early indicator of what can be expected for the long-term clinical impact on vaccine-type HPV-related cancers.

KW - 4HPV vaccine

KW - Gardasil

KW - Genital warts

KW - Human papillomavirus

KW - Quadrivalent human papillomavirus vaccine

KW - Vaccine effectiveness

KW - Vaccine impact

UR - http://www.scopus.com/inward/record.url?scp=84925484657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925484657&partnerID=8YFLogxK

U2 - 10.1007/s12325-015-0178-4

DO - 10.1007/s12325-015-0178-4

M3 - Article

AN - SCOPUS:84925484657

VL - 32

SP - 10

EP - 30

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 1

ER -